Wellington Management Group’s Monopar Therapeutics MNPR Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$13.8M Buy
173,645
+15,208
+10% +$1.63M ﹤0.01% 1160
2026
Q2
$14.7M Sell
158,437
-15,905
-9% -$985K ﹤0.01% 1187
2026
Q1
$9.6M Sell
174,342
-51,726
-23% -$3.12M ﹤0.01% 1255
2025
Q4
$14.8M Sell
226,068
-5,395
-2% -$441K ﹤0.01% 1143
2025
Q3
$18.9M Buy
+231,463
New +$10.3M ﹤0.01% 1048

Other funds holding MNPR

Wellington Management Group's MNPR Position: Q3 2026 in Review

Wellington Management Group increased its Monopar Therapeutics (MNPR) stake by 9.6% in Q3 2026, buying an estimated $1.63M and bringing the position to 173,645 shares worth $13.8M. The position accounts for ﹤0.01% of the portfolio, ranked #1160.

Wellington Management Group first reported a position in MNPR in Q3 2025 and has held it in 5 quarters since. The position peaked at $18.9M in Q3 2025. 106 funds tracked by Wall St. Rank hold MNPR as of Q3 2026.

  • Wellington Management Group held 173,645 shares of Monopar Therapeutics worth $13.8M as of Q3 2026.
  • Wellington Management Group bought 15,208 Monopar Therapeutics shares in Q3 2026, an estimated $1.63M.
  • Monopar Therapeutics made up ﹤0.01% of Wellington Management Group's portfolio in Q3 2026, its #1160 holding.
  • Wellington Management Group first reported a position in Monopar Therapeutics in Q3 2025 and has held it in 5 quarters since.
  • Wellington Management Group's Monopar Therapeutics position peaked at $18.9M in Q3 2025.
  • 106 funds tracked by Wall St. Rank held Monopar Therapeutics as of Q3 2026.

Based on Wellington Management Group's 13F filing for Q3 2026, filed 16 Nov 2026.